Veradermics announces positive Phase 3 Study 302 topline results for VDPHL01 in male pattern hair loss by mariel | Apr 27, 2026 | Portfolio News
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus by mariel | Apr 27, 2026 | Portfolio News
Viridian Therapeutics reports positive Phase 3 REVEAL-1 results for elegrobart in active thyroid eye disease by mariel | Mar 30, 2026 | Portfolio News
Kestra Medical Technologies reports third quarter fiscal 2026 results; raises FY2026 revenue guidance to $93M, representing 55% growth vs. FY2025 by mariel | Mar 17, 2026 | Portfolio News
CytomX Therapeutics reports positive Phase 1 data for CX-2051 (Varseta-M) in colorectal cancer by mariel | Mar 16, 2026 | Portfolio News
AirNexis Therapeutics launches with $200M tranched Series A targeting COPD by mariel | Mar 3, 2026 | Portfolio News
CG Oncology accelerates Phase 3 PIVOT-006 readout to H1 2026 by mariel | Feb 27, 2026 | Portfolio News
FDA grants Priority Review to Vera Therapeutics’ BLA for atacicept in IgA nephropathy; PDUFA date July 7, 2026; completes $800M combined equity and debt financing to support commercial readiness by mariel | Feb 26, 2026 | Portfolio News
OrsoBio reports positive Phase 2a proof-of-concept results for TLC-2716 in hypertriglyceridemia and MASLD by mariel | Feb 10, 2026 | Portfolio News
Veradermics completes IPO; begins trading on NYSE under ticker “MANE” by mariel | Feb 4, 2026 | Portfolio NewsVeradermics closed an oversubscribed Series C in 4Q25 and subsequently completed its IPO, with shares beginning to trade under ticker MANE.
